Pam2Cys
Based on 1 Customer Validation
Pam2Cys (Dipalmitoyl-S-glyceryl-cysteine; S-[2,3-Bis(palmitoyloxy)propyl]cysteine) is a TLR2 agonist and immunostimulant. Pam2Cys binds to TLR2 to activate dendritic cells and trigger the TLR2-dependent NF-κB signaling pathway. Pam2Cys also induces dendritic cell maturation by upregulating the expression of cell surface MHC II molecules. Pam2Cys activates innate immune signaling pathways, drives pro-inflammatory and antimicrobial responses, enhances the expression of macrophage activation markers, increases phagocytic activity, induces the release of IL-12 and pro-inflammatory cytokines, and polarizes macrophages into a pro-inflammatory, antimicrobial phenotype without interfering with IL-10-induced macrophage polarization. Pam2Cys also serves as the lipid moiety in synthetic lipopeptide vaccines and possesses self-adjuvant properties. Pam2Cys enhances the immunogenicity of conjugated peptide segments and induces cellular and humoral immune responses. However, it does not activate CD4 T cells in mouse splenocyte cultures when used alone. Pam2Cys activates pulmonary TLR2 signaling pathways, triggers innate immune responses, recruits neutrophils and macrophages, induces the secretion of various cytokines, alleviates symptoms and damages associated with influenza A virus infection in mice without impairing adaptive immunity. Pam2Cys can be used in studies related to tuberculosis and influenza A virus infection.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 99.82%
- CAS. Nr.: 656831-18-4
- Formel: C38H73NO6S
- Molecular Weight:672.05
-
Speicherung:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biologische Aktivität
Beschreibung
IC50 & Target
|
TLR2 |
In Vitro
The Pam2Cys-containing lipopeptide construct (0.025-0.25 nmol/mL; 5 h) potently activates NF-κB signaling through TLR2 in HEK293 cells[1].
Pam2Cys (10-100 ng/mL; 24 h) increases the phagocytic activity of porcine monocyte-derived macrophages, with a stronger effect at the higher dose[2].
Pam2Cys (10-100 ng/mL; 4 h, 8 h, 24 h) upregulates the gene expression of IL-1β, IL-6, TNF-α, and IL-12p40 at 4, 8, and 24 h, and IL-10 at 4 and 8 h, in porcine monocyte-derived macrophages[2].
Pam2Cys (10-100 ng/mL; 4 h, 8 h, 24 h) upregulates the gene expression of multiple IFN-α subtypes (IFN-α1, IFN-α2, IFN-α5/6, IFN-α9 at 8 h; IFN-α16 at 24 h), downregulates IFN-α3 at 24 h, and does not alter IFN-β expression, in porcine monocyte-derived macrophages[2].
Pam2Cys (10-100 ng/mL; 4 h, 8 h, 24 h) downregulates the gene expression of TLR3, TLR4, TLR5, TLR7, TLR8, and TLR9 in porcine monocyte-derived macrophages at multiple time points (4, 8, 24 h) post-treatment[2].
Pam2Cys (50-100 ng/mL; 72 h) alone does not activate CD4 T cells from L91-immunized mice[3].
Pam2Cys (10 nmol; 24 h) induced primary mouse lung cells to exhibit significantly elevated levels of IL-6, IL-10, MCP-1, IFN-γ, and TNF-α, with no change in IFN-α levels[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:porcine monocyte-derived macrophages
-
Concentration:10-100 ng/mL
-
Incubation Time:4 h, 8 h, 24 h
-
Result:Upregulated the gene expression of multiple IFN-α subtypes (IFN-α1, IFN-α2, IFN-α5/6, IFN-α9 at 8 h; IFN-α16 at 24 h), downregulates IFN-α3 at 24 h, and does not alter IFN-β expression.
Upregulated the gene expression of IL-1β, IL-6, TNF-α, and IL-12p40 at 4, 8, and 24 h, and IL-10 at 4 and 8 h.
Downregulated the gene expression of TLR3, TLR4, TLR5, TLR7, TLR8, and TLR9 in porcine monocyte-derived macrophages at multiple time points (4, 8, 24 h) post-treatment
In Vivo
Immunization with the Pam2Cys-conjugated construct L91 (20-10 nmol per animal; i.p. or s.c., i.p.) induces Th1-skewed dendritic cell activation, robust and enduring CD4 T-cell memory responses, and significantly better protection against Mycobacterium tuberculosis aerosol challenge in mice than BCG, with a 40% reduction in lung bacterial burden relative to BCG[3].
Pam2Cys (20 nmol; i.n.; single dose) provides dose-dependent viral load reduction of up to 88% in mice challenged with mild IAV, with efficacy persisting for at least 7 days post-administration[4].
Pam2Cys (20 nmol; i.n.; single dose) prophylaxis preserves the development of functional, memory-phenotype IAV-specific CD8+ T cells in mice, with enhanced responses in the spleen and reduced but detectable responses in the lungs[4].
Pam2Cys (20 nmol; i.n.; single dose) reduces IAV viral load by over 99% in the trachea and lungs of BALB/c mice, with no effect on nasal turbinate infection[4].
Pam2Cys (20 nmol; i.n.; single dose) provides TLR2-dependent, type 1 interferon-independent protection against virulent IAV in mice, with 92% survival and significant weight loss reduction[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c mice with Influenza A virus infection (male and female, 6-12 weeks old)[4]
-
Dosage:20 nmol
-
Administration:i.n.; single dose
-
Result:Reduced viral titers by 99.4% in the trachea and 99.91% in the lungs relative to saline-treated controls; no reduction was observed in nasal turbinates.
Virus was undetectable in 7 of 11 treated mice’s lungs.\nReduced viral loads by 10-100-fold across nasal turbinates, trachea, and lungs in donor mice relative to saline-treated donors.
Completely prevented transmission to naive recipients when donors were treated 24 or 72 hours prior to challenge; reduced but did not eliminate transmission when donors were treated 5 or 7 days prior to challenge.
-
Animal Model:C57BL/6 mice with Innate immune activation (male and female, 6-12 weeks old); TLR2-deficient (TLR2−/−) on C57BL/6 background (male and female, 6-12 weeks old); BALB/c (male and female, 6-12 weeks old)[4]
-
Dosage:20 nmol
-
Administration:i.n.; single dose
-
Result:Elevated BAL fluid levels of IL-6, IL-10, MCP-1, IFN-γ, and TNF-α significantly, and increased lung populations of neutrophils, interstitial macrophages, alveolar macrophages, lymphocytes, γδ T cells, and activated IFN-γ-producing NK cells significantly in C57BL/6 and BALB/c mice at 72 hours post-administration.
Returned cytokine levels and most innate cell populations to baseline by day 7, but lymphocyte counts remained elevated.
Observed no cytokine or cell population changes in TLR2−/− mice.
Chemical Information
-
CAS. Nr. 656831-18-4
-
Appearance Solid
-
Molecular Weight 672.05
-
Formel C38H73NO6S
-
Color White to off-white
-
SMILES
O=C([C@@H](N)CSCC(OC(CCCCCCCCCCCCCCC)=O)COC(CCCCCCCCCCCCCCC)=O)O
-
Synonyms
Dipalmitoyl-S-glyceryl-cysteine; S-[2,3-Bis(palmitoyloxy)propyl]cysteine
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Lösungsmittel & Löslichkeit
In Vitro:
DMF : 3.33 mg/mL (4.95 mM; ultrasonic and warming and adjust pH to 4 with 1 M HCl and heat to 60°C)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Protokoll
-
Phagocytosis Functional Assay
A phagocytosis functional assay measures the ability of phagocytic cells, such as neutrophils, macrophages, monocytes, or microglia/macrophages, to bind and internalize particulate targets including bacteria, yeast particles, beads, or myelin particles. Fluorescent flow-cytometry assays detect target uptake as fluorescence associated with gated phagocytes, while pH-sensitive dyes such as pHrodo increase signal in acidic phagosomal compartments and therefore preferentially report internalized particles rather than particles remaining outside the cell. Microscopy or high-content imaging can be used to confirm intracellular localization and, in some protocols, to follow uptake kinetics.
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
LPS-Induced Endotoxemia/Systemic Inflammation
Lipopolysaccharide (LPS)-induced endotoxemia is a widely used in vivo model of acute systemic inflammation in which LPS, a Gram-negative bacterial endotoxin, activates innate immune signaling primarily through TLR4, leading to rapid and transient induction of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β in circulation and tissues. This cytokine surge is commonly used as a measurable readout of systemic inflammatory activation and immune dysregulation, and is typically assessed within hours after intraperitoneal LPS administration in mouse models of endotoxemia. The model captures key features of systemic inflammatory response syndrome, including cytokine release, immune cell activation, and downstream tissue responses, and has been used to evaluate anti-inflammatory interventions such as cytokine modulation, lipid mediators, and immune cell-targeting therapies.
-
Primary monocyte-to-macrophage differentiation
Primary human monocytes can be differentiated ex vivo into monocyte-derived macrophages by culturing purified blood monocytes for approximately 5-7 days in macrophage-supporting cytokine conditions; M-CSF commonly yields CD14^high/CD163^high macrophages, while GM-CSF yields a phenotypically distinct macrophage population, so the cytokine condition should be chosen according to the downstream model. The readout of successful differentiation is a combined change in morphology, adherence, surface phenotype, and function: differentiated macrophages become adherent, enlarge, acquire macrophage-associated markers such as CD14, CD68, CD163, CD206, or HLA-DR depending on culture condition, and show increased phagocytic capacity compared with starting monocytes.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Monocyte-derived dendritic cell differentiation
Human monocyte-derived dendritic cells are generated by isolating PBMC-derived monocytes and culturing them with GM-CSF plus IL-4, which produces cells with dendritic-cell antigen-presenting properties, reduced monocyte phenotype, and increased dendritic-cell functional readouts such as antigen uptake, allogeneic T-cell stimulation, and expression of markers including HLA-DR, CD80, CD86, CD83, CD1a, or CD209 depending on protocol and maturation state. The main readout is phenotypic and functional differentiation: immature MoDCs are commonly evaluated by loss or reduction of CD14 with acquisition of dendritic-cell markers and antigen uptake capacity, whereas mature MoDCs are evaluated by increased CD83, CD80, CD86, HLA-DR, and T-cell stimulatory function after exposure to maturation stimuli such as TNF-α or a cytokine/PGE2 cocktail.
Reinheit & Dokumentation
-
Data Sheet (275 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Zeng W, et al. Structural requirement for the agonist activity of the TLR2 ligand Pam2Cys. Amino Acids. 2010;39(2):471-480. [Content Brief]
[2]. Franzoni G, et al. Targeting Toll-Like Receptor 2: Polarization of Porcine Macrophages by a Mycoplasma-Derived Pam2cys Lipopeptide. Vaccines (Basel). 2021;9(7):692. Published 2021 Jun 23. [Content Brief]
[3]. Gowthaman U, et al. Promiscuous peptide of 16 kDa antigen linked to Pam2Cys protects against Mycobacterium tuberculosis by evoking enduring memory T-cell response. J Infect Dis. 2011;204(9):1328-1338. [Content Brief]
[4]. Tan AC, et al. Intranasal administration of the TLR2 agonist Pam2Cys provides rapid protection against influenza in mice. Mol Pharm. 2012;9(9):2710-2718. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMF | 1 mM | 1.4880 mL | 7.4399 mL | 14.8798 mL | 37.1996 mL |
Keywords
- Pam2Cys
- 656831-18-4
- Dipalmitoyl-S-glyceryl-cysteine
- S-[2,3-Bis(palmitoyloxy)propyl]cysteine
- Toll-like Receptor (TLR)
- Influenza Virus
- NF-κB
- HEK293 cells
- CD4 T cells
- MHC Class II
- monocyte-derived macrophages
- Mycobacterium tuberculosis
- neutrophils
- influenza A virus
- NF-κB signaling
- dendritic cells
- TLR2
- Inhibitor
- inhibitor
- inhibit